Sanofi’s shift to immunology, AI-driven R&D, and strong pipeline offset risks from patent cliffs and legal issues. See why ...

The study began on April 11, 2021, and was last updated on August 4, 2025. However, it has been terminated, which could impact the timeline for any potential market release of SAR444881.

Q2 2025 Earnings Call Transcript August 6, 2025 Novavax, Inc. beats earnings expectations. Reported EPS is $0.601, ...

Paris Thursday, August 7, 2025, 10:00 Hrs [IST] Sanofi announces the completion of its acquisition of Vigil Neuroscience, I ...

Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced financial results for its fiscal 2025 third quarter ended June 30, 2025. The Company is hosting a conference call today, August 7, 2025, ...

O'Reilly Automotive Inc. is suing the three major pharmacy benefit managers in the U.S., as well as the three major insulin manufacturers.

Merck & Co (NYSE: MRK) was the biggest spender in pharma M&A during July. The US pharma giant boldly splashed out around $10 ...

Revenue from operations in the quarter under review stood at Rs 2,101 crore as against Rs 1,815 crore in the year-ago period.

Emcure Pharmaceuticals posts a 40.76% rise in Q1 profit after tax to ₹215 crore, driven by solid operational performance ...

Emma Charles shares her vision for healthcare, how AI is reshaping pharma and why access to innovation must be faster and ...

NEW YORK (Reuters) -Woes for U.S. healthcare stocks have worsened this year driven partly by Trump administration policies, ...

In statements to the USA TODAY Network, both the University of Rochester Medical Center, or URMC, and Regeneron noted they ...